Janus Henderson Group PLC Invests $6.99 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Janus Henderson Group PLC purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,799,759 shares of the biotechnology company's stock, valued at approximately $6,985,000. Janus Henderson Group PLC owned approximately 3.92% of Aclaris Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of ACRS. Jefferies Financial Group Inc. boosted its position in Aclaris Therapeutics by 253.9% during the fourth quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company's stock worth $101,000 after purchasing an additional 29,200 shares in the last quarter. Graham Capital Management L.P. acquired a new position in Aclaris Therapeutics in the fourth quarter valued at $35,000. Cubist Systematic Strategies LLC increased its stake in Aclaris Therapeutics by 3,573.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 256,092 shares of the biotechnology company's stock valued at $635,000 after purchasing an additional 249,121 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Aclaris Therapeutics by 41.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 281,119 shares of the biotechnology company's stock worth $697,000 after acquiring an additional 82,000 shares during the last quarter. Finally, Cantor Fitzgerald L. P. acquired a new stake in Aclaris Therapeutics during the fourth quarter worth about $248,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Stock Performance

Aclaris Therapeutics stock remained flat at $1.26 during trading hours on Friday. The company's stock had a trading volume of 404,328 shares, compared to its average volume of 1,182,429. The company's fifty day simple moving average is $1.33 and its 200-day simple moving average is $2.20. The stock has a market cap of $136.43 million, a P/E ratio of -2.42 and a beta of 0.42. Aclaris Therapeutics, Inc. has a 12-month low of $0.95 and a 12-month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, equities analysts anticipate that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price (down previously from $20.00) on shares of Aclaris Therapeutics in a research note on Wednesday, May 14th. Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They set an "overweight" rating on the stock. Wall Street Zen cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Finally, Scotiabank reduced their price objective on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $10.00.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.